All In MedTech

Device Trial Radar · NCT06637293

Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

2,000

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Jan 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Montreal Heart InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 15, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence. The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.

Conditions

  • Primary Care Provider
  • Structural Heart Disease

Interventions

  • DeepECG plateform diagnosis & recommendationsDevice

    EchoNeXT\& ECG-AI algorithm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. sensitivity of cardiology referralsTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Montreal Heart Institute

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.